MANKIND.NS Balance Sheet
Mankind Pharma Ltd.
Profit & Loss Balance Sheet Cash Flow
Balance Sheet · 4 years on file
(FY2022-23 to FY2025-26)
· fetched 2026-08-23 23:37
| Line item | FY2022-23 | FY2023-24 | FY2024-25 | FY2025-26 | Source (XBRL element) |
|---|---|---|---|---|---|
| Property, Plant and Equipment | ₹2,523.80 Cr. | ₹2,931.59 Cr. | ₹2,907.82 Cr. | ₹2,959.56 Cr. | PropertyPlantAndEquipment |
| Capital Work-in-Progress | ₹493.19 Cr. | ₹207.09 Cr. | ₹306.13 Cr. | ₹654.78 Cr. | CapitalWorkInProgress |
| Goodwill | ₹20.02 Cr. | ₹20.02 Cr. | ₹6,492.63 Cr. | ₹6,492.63 Cr. | Goodwill |
| Other Intangible Assets | ₹1,701.46 Cr. | ₹1,588.34 Cr. | ₹9,604.03 Cr. | ₹9,168.26 Cr. | OtherIntangibleAssets |
| Non-current Investments | ₹270.95 Cr. | ₹309.81 Cr. | ₹160.19 Cr. | ₹248.03 Cr. | NoncurrentInvestments |
| Other Non-current Assets | ₹73.36 Cr. | ₹66.28 Cr. | ₹92.26 Cr. | ₹351.96 Cr. | OtherNoncurrentAssets |
| Total Non-current Assets | ₹5,285.06 Cr. | ₹5,313.04 Cr. | ₹20,581.77 Cr. | ₹20,937.14 Cr. | NoncurrentAssets |
| Inventories | ₹1,498.46 Cr. | ₹1,553.46 Cr. | ₹2,093.71 Cr. | ₹2,144.48 Cr. | Inventories |
| Trade Receivables | ₹576.42 Cr. | ₹848.28 Cr. | ₹1,538.34 Cr. | ₹1,729.51 Cr. | TradeReceivablesCurrent |
| Cash and Cash Equivalents | ₹304.82 Cr. | ₹382.01 Cr. | ₹407.36 Cr. | ₹391.69 Cr. | CashAndCashEquivalents |
| Current Investments | ₹1,075.47 Cr. | ₹2,258.11 Cr. | ₹1,690.84 Cr. | ₹1,537.31 Cr. | CurrentInvestments |
| Other Current Assets | ₹663.39 Cr. | ₹691.68 Cr. | ₹802.82 Cr. | ₹805.25 Cr. | OtherCurrentAssets |
| Total Current Assets | ₹4,427.07 Cr. | ₹6,647.51 Cr. | ₹7,175.06 Cr. | ₹7,139.69 Cr. | CurrentAssets |
| Total Assets | ₹9,715.45 Cr. | ₹11,963.25 Cr. | ₹27,759.53 Cr. | ₹28,079.53 Cr. | Assets |
| Equity Share Capital | ₹40.06 Cr. | ₹40.06 Cr. | ₹41.26 Cr. | ₹41.28 Cr. | EquityShareCapital |
| Other Equity | ₹7,395.16 Cr. | ₹9,323.03 Cr. | ₹14,291.13 Cr. | ₹16,259.06 Cr. | OtherEquity |
| Equity Attributable to Owners | ₹7,435.22 Cr. | ₹9,363.09 Cr. | ₹14,332.39 Cr. | ₹16,300.34 Cr. | EquityAttributableToOwnersOfParent |
| Non-controlling Interests | ₹188.07 Cr. | ₹212.70 Cr. | ₹235.79 Cr. | ₹260.71 Cr. | NonControllingInterest |
| Total Equity | ₹7,623.29 Cr. | ₹9,575.79 Cr. | ₹14,568.18 Cr. | ₹16,561.05 Cr. | Equity |
| Long-term Borrowings | ₹28.32 Cr. | ₹32.58 Cr. | ₹5,540.22 Cr. | ₹2,892.66 Cr. | BorrowingsNoncurrent |
| Total Non-current Liabilities | ₹229.02 Cr. | ₹267.74 Cr. | ₹7,527.79 Cr. | ₹5,011.23 Cr. | NoncurrentLiabilities |
| Short-term Borrowings | ₹142.05 Cr. | ₹174.59 Cr. | ₹2,971.23 Cr. | ₹3,418.88 Cr. | BorrowingsCurrent |
| Trade Payables | ₹1,008.18 Cr. | ₹1,102.99 Cr. | ₹1,133.40 Cr. | ₹1,341.33 Cr. | TradePayablesCurrent |
| Other Current Liabilities | ₹122.54 Cr. | ₹170.91 Cr. | ₹202.82 Cr. | ₹172.91 Cr. | OtherCurrentLiabilities |
| Total Current Liabilities | ₹1,863.14 Cr. | ₹2,119.73 Cr. | ₹5,663.56 Cr. | ₹6,507.25 Cr. | CurrentLiabilities |
| Total Equity and Liabilities | ₹9,715.45 Cr. | ₹11,963.25 Cr. | ₹27,759.53 Cr. | ₹28,079.53 Cr. | EquityAndLiabilities |
Every figure above is the exact value of the named XBRL element from MANKIND.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).